Please assess the completion status of the following clinical trial:

Trial Title: A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged above 20 years old~* Patients with Type 1 or Type 2 diabetes mellitus~* Estimated glomerular filtration rate less than 59 mL/min/1.73m2~* Patients not on renal replacement therapy~* Hemoglobin level at baseline : women less than 9.5 g/dL (inclusive) and men less than 10.5 g/dL (inclusive)~* All patients should be on a stable dose of the following medications 4 weeks before enrolment :~* Aspirin 80mg daily unless contraindicated~* Statin to achieve stable and optimal LDL-cholesterol level~* Maximal tolerated dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers~* Anti-hypertensive treatment to maintain blood pressure target of less than 130/80 mmHg or a level achieved without undue side effects~* Oral anti-diabetic drugs or insulin to maintain HbA1C less than 9.5%~Exclusion Criteria:~* Pregnancy, breast feeding or patient has plans of becoming pregnant during the study period~* Known non-diabetic renal disease~* Known cause of anemia not related to chronic kidney disease~* Presence of hemoglobinopathy~* History of pure red cell aplasia~* Known allergy to Darbepoetin alfa~* Severe liver impairment (\>= 3x ULN of ALT)~* Poorly controlled hypertension, systolic BP \>= 160mmHg or diastolic BP \>= 100mmHg~* Significant cardiovascular disease within 3 months of enrolment including acute coronary syndrome, cardiac revascularization procedure, transient ischemic attack and cerebrovascular accident~* History of major gastrointestinal bleeding in the 5 years prior to consent~* Investigational drugs within 30 days of enrolment~* Any other medical conditions that is considered as unsuitable for the study by investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Receive Darbepoetin alfa
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).